By 60, they've dropped to roughly 80 ng/mL
An international multi-centre study has shown that the drug semaglutide, administered to treat diabetes and obesity, protects the kidney in obese patients with chronic kidney disease
Clinical Evidence and Safety Data for Dual-Compound GLP-1 Protocols Published research specifically examining concurrent semaglutide and tirzepatide use in the same patient remains limited, largely because tirzepatide itself already contains GLP-1 agonism
It would be ridiculous not to, she said
Oral Administration Subcutaneous (SubQ) Injection Injected just under the skin, typically near the site of injury Best for targeted healing of tendons, ligaments, joints, and muscles Fast absorption and high local bioavailability Injection sites : Shoulder issues : Lateral deltoid, upper bicep Knee or patella tendonitis : Around the lower thigh or above kneecap Ankle or Achilles pain : Outer calf or above heel Elbow or wrist pain : Forearm or triceps area How to inject SubQ : Use an insulin syringe (2931G, inch) Pinch skin, insert needle at a 4590 angle Inject slowly, rotate injection sites daily Inject 12 inches away from direct injury to avoid tissue trauma Intramuscular (IM) Injection Less common, but can be used when injecting deeper tissues or larger muscles Administer into lateral deltoid, glutes, or vastus lateralis May increase discomfort
How semaglutide works at the cellular level Understanding the mechanism explains the timeline